肝病患者中乳糜泻的患病率:系统综述与荟萃分析
该系统综述与荟萃分析检索PubMed和EMBASE至2022年1月,纳入20篇文章,评估隐源性肝硬化、全因肝硬化、隐源性转氨酶升高及全因转氨酶升高患者中乳糜泻的合并患病率。隐源性肝硬化中活检确诊乳糜泻的合并患病率为4.6%(95%CI 2.2%-7.5%),隐源性转氨酶升高为5.7%(95%CI 3.2%-8.8%),全因肝硬化为0.8%(95%CI 0%-3.4%)。作者认为隐源性肝硬化和隐源性转氨酶升高患者应被视为乳糜泻高危人群。
要点
- 隐源性肝硬化患者活检确诊乳糜泻合并患病率为4.6%(95%CI 2.2%-7.5%)。
- 隐源性转氨酶升高患者活检确诊乳糜泻合并患病率为5.7%(95%CI 3.2%-8.8%)。
- 全因肝硬化患者活检确诊乳糜泻合并患病率为0.8%(95%CI 0%-3.4%),与一般人群相似。
核心结论
- 隐源性肝硬化和隐源性转氨酶升高患者中近1/20患有乳糜泻,两者均应被视为乳糜泻高危人群。
- 全因肝硬化患者中乳糜泻患病率与一般人群相似,但因其肝病理有逆转可能,可能值得筛查乳糜泻。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed和EMBASE截至2022年1月。
- 纳入对隐源性肝硬化、全因肝硬化、隐源性转氨酶升高和全因转氨酶升高患者进行乳糜泻血清学检测和/或肠道活检的横断面、病例对照和前瞻性队列研究。
- 共筛选6871篇文章,最终纳入20篇文章,对隐源性肝硬化、全因肝硬化和隐源性转氨酶升高进行3项荟萃分析;全因转氨酶升高组因研究间差异显著,对4项研究进行定性综述而非荟萃分析。
主要发现
- 隐源性肝硬化中活检确诊乳糜泻的合并患病率为4.6%(95%CI 2.2%-7.5%)。
- 全因肝硬化中活检确诊乳糜泻的合并患病率为0.8%(95%CI 0%-3.4%)。
- 隐源性转氨酶升高中活检确诊乳糜泻的合并患病率为5.7%(95%CI 3.2%-8.8%)。
局限性
- 全因转氨酶升高组因研究间差异显著,未进行荟萃分析,仅对4项研究进行定性综述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A subset of patients with celiac disease (CeD) has liver involvement in the form of hypertransaminasemia, liver cirrhosis, and autoimmune hepatitis. We conducted a systematic review with meta-analyses to determine the pooled prevalence of CeD in patients with cryptogenic cirrhosis, all-cause cirrhosis, cryptogenic hypertransaminasemia, and all-cause hypertransaminasemia. METHODS: We searched PubMed and EMBASE up to January 2022. Cross-sectional, case-control, and prospective cohort studies performing serological tests and/or intestinal biopsy for CeD on patients with cryptogenic cirrhosis, all-cause cirrhosis, cryptogenic hypertransaminasemia, and all-cause hypertransaminasemia were included to calculate pooled estimates of seroprevalence and the prevalence of biopsy-confirmed CeD in these 4 groups. RESULTS: Of 6,871 articles screened, 20 articles were included finally in 3 meta-analyses for cryptogenic cirrhosis, all-cause cirrhosis, and cryptogenic hypertransaminasemia. For the all-cause hypertransaminasemia group, a qualitative review of 4 studies was conducted instead of a meta-analysis due to significant differences in studies. The pooled prevalence (95% confidence interval) of biopsy-confirmed CeD in cryptogenic cirrhosis was 4.6% (2.2%-7.5%) while the pooled prevalence of biopsy-confirmed CeD in all-cause cirrhosis was 0.8% (0%-3.4%). The pooled prevalence of biopsy-confirmed CeD in cryptogenic hypertransaminasemia was 5.7% (3.2%-8.8%). DISCUSSION: Nearly 1 in 20 patients each with cryptogenic cirrhosis and cryptogenic hypertransaminasemia have CeD; hence, they should both be considered high-risk groups for CeD. While the prevalence of CeD in those with all-cause cirrhosis is similar to that in general population, it may be worth screening them for CeD because liver pathology has the potential for reversal in them.
引用
- Yoosuf S, Singh P, Khaitan A, et al. Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses. Am J Gastroenterol. 2022. PMID: 36599134. doi:10.14309/ajg.0000000000002123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。